Investment Thesis
Rapport is a pre-revenue biotech company with no sales and burning $87.5M annually in operating cash, leaving only 7 months of cash runway at current burn rates. While the balance sheet is strong with $484.7M equity and zero debt, the company faces critical dependency on successful clinical trials, regulatory approval, and imminent capital raises to survive. Absent major near-term milestones or funding announcements, the cash depletion risk is severe and fundamentally unsustainable.
Strengths
- Fortress balance sheet with $484.7M stockholders equity and zero long-term debt
- Exceptional liquidity (26.17x current ratio) providing near-term operational flexibility
- Improving EPS trend year-over-year (+24.3%), indicating loss reduction relative to share base
Risks
- Pre-revenue stage with no commercial traction or sales generation capability
- Severe cash burn of -$87.5M annually with only ~6-7 months of runway at current rates
- Existential dependency on successful clinical trials, FDA approval, and external capital raises for survival
- Negative returns destroying shareholder value (ROE -23%, ROA -21.8%)
- High execution risk on pipeline drug candidates with no near-term revenue visibility
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Clinical trial progression, FDA milestone dates, and regulatory feedback
- Equity financing announcements, capital raise amounts, and burn rate sustainability
- Operating loss trajectory and path to first revenue-generating drug approval
Financial Metrics
Revenue
N/A
Net Income
-111.5M
EPS (Diluted)
$-2.86
Free Cash Flow
-88.1M
Total Assets
512.4M
Cash
52.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-23.0%
ROA
-21.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
26.17x
Quick Ratio
26.17x
Debt/Equity
0.00x
Debt/Assets
5.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T00:30:25.345007 |
Data as of: 2025-12-31 |
Powered by Claude AI